Frankfurt - Delayed Quote EUR

PTC Therapeutics, Inc. (BH3.F)

42.80

+1.40

+(3.38%)

At close: 8:04:03 AM GMT+2

PTC Therapeutics (PTCT) Earnings Expected to Grow: Should You Buy?

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 6 days ago

PTCT
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2025 financial results and provide an update on the company's business and outlook on Tuesday, May 6, at 4:30 p.m. ET.

PR Newswire 6 days ago

PTCT
Biotech stocks slide as Marks resignation seen being negative for sector

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit

TipRanks 22 days ago

GLPG

GLPGF

PTCT
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 24, 2025, the company approved non-statutory stock options to purchase an aggregate of 12,000 shares of its common stock and 28,220 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 35 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.

PR Newswire 26 days ago

PTCT
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has adopted the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to not renew the authorization of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy. While this action effectively removes the drug's conditional marketing authorization in the European Economic Area, the EC indicated that individual countries with

PR Newswire 26 days ago

PTCT
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies

PTC Therapeutics, Inc. (NASDAQ: PTCT) today shared new data being presented from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. These data provide further evidence of the potential meaningful benefits of sepiapterin treatment for the full spectrum of phenylketonuria (PKU) patients, including significant diet liberalization.

PR Newswire last month

PTCT
Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?

Kiniksa Pharmaceuticals (KNSA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks last month

KNSA

PTCT
PTC Therapeutics, Inc. (NASDAQ:PTCT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

The analysts might have been a bit too bullish on PTC Therapeutics, Inc. ( NASDAQ:PTCT ), given that the company fell...

Simply Wall St. last month

PTCT
We Might See A Profit From PTC Therapeutics, Inc. (NASDAQ:PTCT) Soon

We feel now is a pretty good time to analyse PTC Therapeutics, Inc.'s ( NASDAQ:PTCT ) business as it appears the...

Simply Wall St. last month

PTCT
Q4 2024 PTC Therapeutics Inc Earnings Call

Q4 2024 PTC Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents last month

PTCT

NVS
PTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ...

PTC Therapeutics Inc (PTCT) surpasses revenue expectations, strengthens cash position, and prepares for multiple product launches in 2025.

GuruFocus.com last month

PTCT

NVS
PTC Therapeutics (PTCT) Reports Q4 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks last month

PTCT
PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of 75% and 3.96%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

PTCT
PTC Therapeutics: Q4 Earnings Snapshot

The Warren, New Jersey-based company said it had a loss of 85 cents per share. Losses, adjusted for one-time gains and costs, came to 24 cents per share. The results topped Wall Street expectations.

Associated Press Finance last month

PTCT
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter ending December 31, 2024.

PR Newswire last month

PTCT
Countdown to PTC Therapeutics (PTCT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

Besides Wall Street's top -and-bottom-line estimates for PTC Therapeutics (PTCT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.

Zacks last month

PTCT
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

PTCT

EDIT
PTC Therapeutics to Participate in Upcoming Investor Conferences

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will participate in fireside chats at the following investor conferences:

PR Newswire 2 months ago

PTCT
PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for vatiquinone for the treatment of children and adults living with Friedreich's ataxia (FA). The application has been granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of Aug. 19, 2025.

PR Newswire 2 months ago

PTCT
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2024 financial results and provide an update on the company's business and outlook on Thursday, Feb. 27, at 4:30 p.m. EST.

PR Newswire 2 months ago

PTCT

Performance Overview

Return	BH3.F	S&P 500 (^GSPC)
YTD	--	-8.60%
1-Year	+78.33%	+6.02%
3-Year	+16.30%	+25.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

PTC Therapeutics, Inc. (BH3.F)

PTC Therapeutics (PTCT) Earnings Expected to Grow: Should You Buy?

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results

Biotech stocks slide as Marks resignation seen being negative for sector

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe

PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies

Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?

PTC Therapeutics, Inc. (NASDAQ:PTCT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

We Might See A Profit From PTC Therapeutics, Inc. (NASDAQ:PTCT) Soon

Q4 2024 PTC Therapeutics Inc Earnings Call

PTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ...

PTC Therapeutics (PTCT) Reports Q4 Earnings: What Key Metrics Have to Say

PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates

PTC Therapeutics: Q4 Earnings Snapshot

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Countdown to PTC Therapeutics (PTCT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

PTC Therapeutics to Participate in Upcoming Investor Conferences

PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

Performance Overview